Search
Oxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.
International brands: Staficilin-NCyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigational[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome. … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.
Karaya gum
go.drugbank.com/drugs/DB10535ApprovedKaraya gum allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingMosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Fosnetupitant is the pro-drug form of netupitant [FDA label].
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnOn August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]
Fexapotide
go.drugbank.com/drugs/DB05493InvestigationalNX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.
Categories: Drugs Used in Benign Prostatic HypertrophyAtacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.
Synonyms: TACI-IGPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalThese resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a … Individual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940].